SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001193125-19-037708
Filing Date
2019-02-13
Accepted
2019-02-13 14:39:32
Documents
2
Group Members
ESSEX WOODLANDS HEALTH VENTURES FUND V, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B, L.P.ESSEX WOODLANDS HEALTH VENTURES V, L.L.C.ESSEX WOODLANDS HEALTH VE

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d708268dsc13ga.htm SC 13G/A 226679
2 EX-99.1 d708268dex991.htm EX-99.1 24923
  Complete submission text file 0001193125-19-037708.txt   253636
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Subject) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88023 | Film No.: 19596332
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1

Mailing Address 21 WATERWAY AVENUE SUITE 225 THE WOODLANDS TX 77380
Business Address 21 WATERWAY AVENUE SUITE 225 THE WOODLANDS TX 77380 2813641555
Essex Woodlands Health Ventures VIII, L.L.C. (Filed by) CIK: 0001632027 (see all company filings)

IRS No.: 261923296
Type: SC 13G/A